Benitec Biopharma FY2025 net loss $37.9M ($1.05/sh); BB-301 DSMB clears Cohort 2 enrollment

Benitec Biopharma Inc.

Net loss $37.9M ($1.05/share) vs $22.4M ($1.22/share) in FY2024; total expenses $41.8M (up 86%).
R&D expense $18.3M (up 17%) on BB-301 clinical development; G&A $23.4M (up 235%) driven by stock-based comp $14.5M.
Cash and equivalents $97.7M (up from $50.9M) after equity offerings.
DSMB recommended continuation; Cohort 2 enrollment and interim Cohort 1 data both expected Q4 2025.
BB-301 Phase 1b/2a for OPMD with dysphagia; no revenue reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.